Stem definition | Drug id | CAS RN |
---|---|---|
4496 | 74050-97-8 |
None
None
Date | Agency | Company | Orphan |
---|---|---|---|
Jan. 14, 1986 | FDA | JANSSEN PHARMS |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Extrapyramidal disorder | 207.38 | 34.03 | 50 | 1232 | 11720 | 50592122 |
Weight increased | 128.01 | 34.03 | 73 | 1209 | 201818 | 50402024 |
Cervix neoplasm | 72.82 | 34.03 | 11 | 1271 | 203 | 50603639 |
Neuroleptic malignant syndrome | 61.42 | 34.03 | 19 | 1263 | 11111 | 50592731 |
Central obesity | 55.64 | 34.03 | 11 | 1271 | 1011 | 50602831 |
Intentional self-injury | 34.32 | 34.03 | 15 | 1267 | 23097 | 50580745 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Extrapyramidal disorder | 290.45 | 32.53 | 84 | 2647 | 10747 | 29561049 |
Weight increased | 134.47 | 32.53 | 85 | 2646 | 76582 | 29495214 |
Neuroleptic malignant syndrome | 131.09 | 32.53 | 51 | 2680 | 16097 | 29555699 |
Akathisia | 94.87 | 32.53 | 32 | 2699 | 6710 | 29565086 |
Peptostreptococcus infection | 54.53 | 32.53 | 8 | 2723 | 27 | 29571769 |
Blood pressure measurement | 54.37 | 32.53 | 10 | 2721 | 164 | 29571632 |
Incorrect route of product administration | 44.06 | 32.53 | 21 | 2710 | 10780 | 29561016 |
Tardive dyskinesia | 43.98 | 32.53 | 17 | 2714 | 5241 | 29566555 |
Parkinsonism | 41.91 | 32.53 | 18 | 2713 | 7260 | 29564536 |
Antipsychotic drug level below therapeutic | 38.45 | 32.53 | 12 | 2719 | 1962 | 29569834 |
Weight bearing difficulty | 38.33 | 32.53 | 10 | 2721 | 861 | 29570935 |
Muscle rigidity | 37.48 | 32.53 | 18 | 2713 | 9393 | 29562403 |
Suicide attempt | 36.44 | 32.53 | 28 | 2703 | 34082 | 29537714 |
Delusion | 34.48 | 32.53 | 18 | 2713 | 11198 | 29560598 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Extrapyramidal disorder | 482.09 | 28.09 | 127 | 3427 | 19425 | 64475753 |
Weight increased | 243.85 | 28.09 | 149 | 3405 | 213199 | 64281979 |
Neuroleptic malignant syndrome | 138.56 | 28.09 | 52 | 3502 | 24944 | 64470234 |
Akathisia | 82.61 | 28.09 | 29 | 3525 | 11481 | 64483697 |
Cervix neoplasm | 65.56 | 28.09 | 11 | 3543 | 179 | 64494999 |
Muscle rigidity | 54.22 | 28.09 | 24 | 3530 | 17449 | 64477729 |
Peptostreptococcus infection | 52.67 | 28.09 | 8 | 3546 | 66 | 64495112 |
Blood pressure measurement | 51.31 | 28.09 | 10 | 3544 | 386 | 64494792 |
Tardive dyskinesia | 50.45 | 28.09 | 19 | 3535 | 9159 | 64486019 |
Intentional self-injury | 45.39 | 28.09 | 25 | 3529 | 29019 | 64466159 |
Central obesity | 43.23 | 28.09 | 11 | 3543 | 1444 | 64493734 |
Catatonia | 42.70 | 28.09 | 16 | 3538 | 7604 | 64487574 |
Parkinsonism | 42.21 | 28.09 | 19 | 3535 | 14354 | 64480824 |
Delusion | 38.12 | 28.09 | 19 | 3535 | 17995 | 64477183 |
Incorrect route of product administration | 36.25 | 28.09 | 20 | 3534 | 23278 | 64471900 |
Hallucination, auditory | 36.24 | 28.09 | 18 | 3536 | 16921 | 64478257 |
Injection site erosion | 34.78 | 28.09 | 6 | 3548 | 116 | 64495062 |
Pancreatitis necrotising | 34.60 | 28.09 | 11 | 3543 | 3206 | 64491972 |
Dystonia | 34.41 | 28.09 | 18 | 3536 | 18847 | 64476331 |
Weight bearing difficulty | 32.23 | 28.09 | 10 | 3544 | 2693 | 64492485 |
Treatment noncompliance | 31.48 | 28.09 | 23 | 3531 | 43459 | 64451719 |
Suicide attempt | 31.10 | 28.09 | 28 | 3526 | 70979 | 64424199 |
Hypertonia | 30.84 | 28.09 | 12 | 3542 | 6313 | 64488865 |
Psychotic disorder | 28.97 | 28.09 | 20 | 3534 | 34558 | 64460620 |
None
Source | Code | Description |
---|---|---|
MeSH PA | D014150 | Antipsychotic Agents |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D002492 | Central Nervous System Depressants |
MeSH PA | D011619 | Psychotropic Drugs |
MeSH PA | D014149 | Tranquilizing Agents |
MeSH PA | D018726 | Anti-Dyskinesia Agents |
MeSH PA | D000932 | Antiemetics |
MeSH PA | D015259 | Dopamine Agents |
MeSH PA | D018492 | Dopamine Antagonists |
MeSH PA | D005765 | Gastrointestinal Agents |
MeSH PA | D018377 | Neurotransmitter Agents |
MeSH PA | D018373 | Peripheral Nervous System Agents |
CHEBI has role | CHEBI:48279 | serotonin antagonists |
CHEBI has role | CHEBI:48561 | dopaminergic antagonists |
CHEBI has role | CHEBI:50919 | antiemetico |
CHEBI has role | CHEBI:65190 | typical antipsychotic drugs |
CHEBI has role | CHEBI:66956 | antidyskinetic agent |
FDA EPC | N0000180182 | Typical Antipsychotic |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Chronic schizophrenia | indication | 83746006 | |
Neuroleptic malignant syndrome | contraindication | 15244003 | DOID:14464 |
Senile dementia | contraindication | 15662003 | |
Agranulocytosis | contraindication | 17182001 | DOID:12987 |
Thyrotoxic crisis | contraindication | 29028009 | DOID:12837 |
Torsades de pointes | contraindication | 31722008 | |
Parkinsonism | contraindication | 32798002 | |
Hypothyroidism | contraindication | 40930008 | DOID:1459 |
Hypokalemia | contraindication | 43339004 | |
Low blood pressure | contraindication | 45007003 | |
Extrapyramidal disease | contraindication | 76349003 | |
Leukopenia | contraindication | 84828003 | DOID:615 |
Tardive dyskinesia | contraindication | 102449007 | |
Prolonged QT interval | contraindication | 111975006 | |
Seizure disorder | contraindication | 128613002 | |
Hypomagnesemia | contraindication | 190855004 | |
Angina pectoris | contraindication | 194828000 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Retention of urine | contraindication | 267064002 | |
Neutropenic disorder | contraindication | 303011007 | DOID:1227 |
Coma | contraindication | 371632003 | |
Breastfeeding (mother) | contraindication | 413712001 | |
Central nervous system depression | contraindication | 418072004 | |
Acquired torsion dystonia | contraindication | 433493000 | |
Congenital long QT syndrome | contraindication | 442917000 | |
Carcinoma of female breast | contraindication | 447782002 | |
Smokes tobacco daily | contraindication | 449868002 | |
Drug Induced CNS Depression | contraindication |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 7.95 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
D(2) dopamine receptor | GPCR | INVERSE AGONIST | Ki | 9.34 | CHEMBL | CHEMBL | |||
D(3) dopamine receptor | GPCR | Ki | 8.46 | CHEMBL | |||||
D(4) dopamine receptor | GPCR | Ki | 8.24 | CHEMBL | |||||
D(1A) dopamine receptor | GPCR | Ki | 6.85 | CHEMBL |
ID | Source |
---|---|
D01898 | KEGG_DRUG |
4018124 | VUID |
N0000179148 | NUI |
4018123 | VANDF |
4018124 | VANDF |
CHEBI:31664 | CHEBI |
CHEBI:5613 | CHEBI |
CHEMBL1200986 | ChEMBL_ID |
C033563 | MESH_SUPPLEMENTAL_RECORD_UI |
AC20PJ4101 | UNII |
52919 | PUBCHEM_CID |
3559 | PUBCHEM_CID |
DB00502 | DRUGBANK_ID |
26420 | RXNORM |
11634 | MMSL |
3626 | MMSL |
4816 | MMSL |
4817 | MMSL |
583 | MMSL |
d00027 | MMSL |
001518 | NDDF |
001519 | NDDF |
10756001 | SNOMEDCT_US |
386837002 | SNOMEDCT_US |
412196004 | SNOMEDCT_US |
C0062103 | UMLSCUI |
C0018546 | UMLSCUI |
918 | INN_ID |
D006220 | MESH_DESCRIPTOR_UI |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Haloperidol Decanoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9295 | INJECTION | 100 mg | INTRAMUSCULAR | ANDA | 20 sections |
Haloperidol Decanoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9296 | INJECTION | 100 mg | INTRAMUSCULAR | ANDA | 20 sections |
Haloperidol Decanoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0703-7121 | INJECTION | 50 mg | INTRAMUSCULAR | ANDA | 22 sections |
Haloperidol Decanoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0703-7123 | INJECTION | 50 mg | INTRAMUSCULAR | ANDA | 22 sections |
Haloperidol Decanoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0703-7131 | INJECTION | 100 mg | INTRAMUSCULAR | ANDA | 22 sections |
Haloperidol Decanoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0703-7133 | INJECTION | 100 mg | INTRAMUSCULAR | ANDA | 22 sections |
Haloperidol Decanoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10147-0921 | INJECTION | 50 mg | INTRAMUSCULAR | NDA AUTHORIZED GENERIC | 25 sections |
Haloperidol Decanoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10147-0922 | INJECTION | 100 mg | INTRAMUSCULAR | NDA AUTHORIZED GENERIC | 25 sections |
haloperidol decanoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-831 | INJECTION, SOLUTION | 50 mg | INTRAMUSCULAR | ANDA | 23 sections |
haloperidol decanoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-833 | INJECTION, SOLUTION | 100 mg | INTRAMUSCULAR | ANDA | 23 sections |
haloperidol decanoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-834 | INJECTION, SOLUTION | 500 mg | INTRAMUSCULAR | ANDA | 23 sections |
Haldol Decanoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50458-253 | INJECTION | 50 mg | INTRAMUSCULAR | NDA | 23 sections |
Haldol Decanoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50458-254 | INJECTION | 100 mg | INTRAMUSCULAR | NDA | 23 sections |
Haloperidol Decanoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-469 | INJECTION | 50 mg | INTRAMUSCULAR | ANDA | 22 sections |
Haloperidol Decanoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-471 | INJECTION | 100 mg | INTRAMUSCULAR | ANDA | 22 sections |
Haloperidol Decanoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-471 | INJECTION | 100 mg | INTRAMUSCULAR | ANDA | 22 sections |
Haloperidol Decanoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64725-0471 | INJECTION | 100 mg | INTRAMUSCULAR | ANDA | 13 sections |
Haloperidol Decanoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67457-381 | INJECTION | 100 mg | INTRAMUSCULAR | ANDA | 14 sections |
Haloperidol Decanoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67457-382 | INJECTION | 50 mg | INTRAMUSCULAR | ANDA | 14 sections |
Haloperidol Decanoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67457-409 | INJECTION | 100 mg | INTRAMUSCULAR | ANDA | 14 sections |
Haloperidol Decanoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67457-410 | INJECTION | 50 mg | INTRAMUSCULAR | ANDA | 14 sections |
Haloperidol Decanoate | Human Prescription Drug Label | 1 | 68083-137 | INJECTION | 50 mg | INTRAMUSCULAR | ANDA | 20 sections |
Haloperidol Decanoate | Human Prescription Drug Label | 1 | 68083-138 | INJECTION | 100 mg | INTRAMUSCULAR | ANDA | 20 sections |
HALOPERIDOL DECANOATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70069-030 | INJECTION | 50 mg | INTRAMUSCULAR | ANDA | 17 sections |
HALOPERIDOL DECANOATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70069-031 | INJECTION | 100 mg | INTRAMUSCULAR | ANDA | 17 sections |
HALOPERIDOL DECANOATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70069-381 | INJECTION | 50 mg | INTRAMUSCULAR | ANDA | 17 sections |
HALOPERIDOL DECANOATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70069-382 | INJECTION | 50 mg | INTRAMUSCULAR | ANDA | 17 sections |
HALOPERIDOL DECANOATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70069-383 | INJECTION | 100 mg | INTRAMUSCULAR | ANDA | 17 sections |
HALOPERIDOL DECANOATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70069-384 | INJECTION | 100 mg | INTRAMUSCULAR | ANDA | 17 sections |
haloperidol decanoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70518-1281 | INJECTION, SOLUTION | 100 mg | INTRAMUSCULAR | ANDA | 21 sections |